Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus

This study explored the details of the immune response after autologous hematopoietic stem cell transplantation (AHSCT) treatment in type 1 diabetes mellitus. Peripheral blood mononuclear cells (PBMCs) from 18 patients with type 1 diabetes mellitus were taken at baseline and 12 months after AHSCT or...

Full description

Saved in:
Bibliographic Details
Published in:Stem cell research & therapy 2017-04, Vol.8 (1), p.90-90, Article 90
Main Authors: Ye, Lei, Li, Li, Wan, Bing, Yang, Minglan, Hong, Jie, Gu, Weiqiong, Wang, Weiqing, Ning, Guang
Format: Article
Language:English
Subjects:
Adolescent
Autografts
Cell culture
Cells, Cultured
Cytokines
Cytokines - genetics
Cytokines - metabolism
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 1 - therapy
Female
Flow cytometry
Forkhead Transcription Factors - genetics
Forkhead Transcription Factors - metabolism
Foxp3 protein
Gene expression
Glutamate decarboxylase
Helper cells
Hematopoietic stem cell
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Immune response
Inflammation
Insulin
Interferon
Interleukin 10
Interleukin 12
Interleukin 2
Laboratories
Leukocytes (mononuclear)
Lymphocytes
Lymphocytes T
Male
Multiple sclerosis
Peripheral blood mononuclear cells
Regulartory T cell
Stem cell transplantation
Stem cells
T cell receptors
Th1 cell
Th1 Cells - cytology
Th1 Cells - immunology
Th17 cell
Th17 Cells - cytology
Th17 Cells - immunology
Transplantation
Transplantation, Autologous - adverse effects
Type 1 diabetes mellitus
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study explored the details of the immune response after autologous hematopoietic stem cell transplantation (AHSCT) treatment in type 1 diabetes mellitus. Peripheral blood mononuclear cells (PBMCs) from 18 patients with type 1 diabetes mellitus were taken at baseline and 12 months after AHSCT or insulin-only therapy. The lymphocyte proliferation, mRNA expression and secretion of pro-inflammatory and anti-inflammatory cytokines belonging to T-helper type 1 (Th1), T-helper type 17 (Th17) and regulatory T (Treg) cells in PBMC culture supernatants were assessed. Compared with patients receiving insulin-only treatment, the patients receiving AHSCT treatment showed better residual C-peptide secretion, lower anti-GAD titers and less exogenous insulin dosages after 12 months of follow-up. AHSCT treatment was associated with significantly reduced Th1 and Th17 cell proportions as well as decreased IFN-γ, IL-2, IL-12p40 and IL-17A levels in the PBMC culture supernatants (all P 
ISSN:1757-6512
1757-6512
DOI:10.1186/s13287-017-0542-1